Congress Materials – American Urology Association (AUA 2026)
2026 American Urological Association | May 15 -18 | Las Vegas, NV
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Real-World Evidence Study Assessing the Prevalence and Prognostic Value of FGFR Alterations in Patients With Intermediate Risk Non–Muscle-Invasive Bladder Cancer
Joshua Meeks, Morgan Roupret, Songjun Xu, Jiarui Zhang, Shibu Thomas, Guneet Walia, Sydney Akapame, Lauren Crow, Huimin Liao, Nicole Stone, Spyros Triantos, Neil Beeharry
Association of Genomic Disease Burden Markers and Programmed Death-Ligand 1 With Clinical Outcomes in Patients With Muscle-Invasive Bladder Cancer Treated With Gemcitabine Intravesical System + Cetrelimab (CET) or CET Alone in the Phase 2 SunRISe-4 Trial
Felix Guerrero-Ramos, Andrea Necchi, Neal Shore, Paul L. Crispen, Bernadett Szabados, Evanguelos Xylinas, Karen Urtishak, Sebastiano Battaglia, Flavia Pinho, Mohamad Hasan, Cinty Gong, Hind Stitou, Sumeet Bhanvadia, Sarah P. Psutka
Comparative Effectiveness of Gemcitabine Intravesical System vs Real-World Intravesical Chemotherapy in BCG-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer With Carcinoma in Situ: An Indirect Treatment Comparison Using an External Control Group
Girish S. Kulkarni, Jennifer Bepple, Daniel Lee, Shreyas Joshi, Yi Zhe Wang, Sarah Cote, Xi Wang, Dee Lin, Jianming He, Ruhee Jain, Hussein Sweiti, Shalaka Hampras, Michael Kelleher, Lydia Almeida, Cheryl Xiang, Petros Grivas
MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics
Christopher M. Pieczonka, Won Sik Ham, Jordan Alger, Jose M. Calderon, Meggan Tammaro, Marija Todorovic, Won Kim, Nicole L. Stone, Spyros Triantos, José Luis Domínguez-Escrig
MoonRISe-3: a Phase 3 Study of Erda-iDRS, an Erdafitinib Intravesical Drug-Releasing System, vs Intravesical Chemotherapy in Patients With Bacillus Calmette-Guérin–Treated High-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations
Brian Mazzarella, Cinty Gong, Maarten Schuit, Spyros Triantos, Wolfgang Jessner, Won Kim, Nicole L. Stone, Sydney Akapame, Morgan Roupret
Quality Care Measures Among Patients With High-Risk Non-Muscle Invasive Bladder Cancer With Papillary Carcinoma or Carcinoma in Situ Receiving Front-Line Bacillus Calmette-Guérin or Other Intravesical Therapies
Ali Raza Khaki, Mukul Singhal, Bruno Emond, Carmine Rossi, Rebecca Bungay, Steven Liu, Dominic Pilon, Michael D. Fabrizio
Real-World Outcomes of BCG-Retreatment After BCG Failure in Patients With Papillary Only High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Study in The American Urological Association's Quality Registry
Joshua J. Meeks, Yi Zhe Wang, Sarah Cote, Dee Lin, Michael Kelleher, Sumeet Bhanvadia
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.